La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Cochlear Résultats passés

Passé contrôle des critères 4/6

Cochlear a connu une croissance annuelle moyenne de ses bénéfices de 22.8%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en hausse à 5.6% par an. Les revenus ont augmenté de en hausse à un taux moyen de 10.6% par an. Le rendement des capitaux propres de Cochlear est 19.4% et ses marges nettes sont de 16%.

Informations clés

22.8%

Taux de croissance des bénéfices

20.5%

Taux de croissance du BPA

Medical Equipment Croissance de l'industrie	5.8%
Taux de croissance des recettes	10.6%
Rendement des fonds propres	19.4%
Marge nette	16.0%
Prochaine mise à jour des résultats	14 Feb 2025

Mises à jour récentes des performances passées

Recent updates

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Aug 16

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 04

Cochlear (ASX:COH) Could Be Struggling To Allocate Capital

Sep 12

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Jun 05

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

Apr 05

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Mar 04

Is Cochlear (ASX:COH) A Risky Investment?

Dec 19

Is Cochlear Limited (ASX:COH) Worth AU$205 Based On Its Intrinsic Value?

Nov 16

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Oct 25

Should Shareholders Reconsider Cochlear Limited's (ASX:COH) CEO Compensation Package?

Oct 11

Cochlear's (ASX:COH) Upcoming Dividend Will Be Larger Than Last Year's

Aug 28

Here's Why Cochlear (ASX:COH) Can Manage Its Debt Responsibly

Aug 23

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Jul 16

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

May 19

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Apr 09

Estimating The Intrinsic Value Of Cochlear Limited (ASX:COH)

Feb 04

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Dec 24

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

Oct 30

This Is Why We Think Cochlear Limited's (ASX:COH) CEO Might Get A Pay Rise Approved By Shareholders

Oct 12

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

Oct 06

Returns On Capital Signal Tricky Times Ahead For Cochlear (ASX:COH)

Aug 16

Cochlear (ASX:COH) Has A Pretty Healthy Balance Sheet

Jun 24

A Look At The Intrinsic Value Of Cochlear Limited (ASX:COH)

May 17

There Are Reasons To Feel Uneasy About Cochlear's (ASX:COH) Returns On Capital

Apr 29

These 4 Measures Indicate That Cochlear (ASX:COH) Is Using Debt Reasonably Well

Mar 20

Insider Buying: The Cochlear Limited (ASX:COH) Independent Non-Executive Director Just Bought 24% More Shares

Mar 02

Cochlear Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 20

Ventilation des recettes et des dépenses

Comment Cochlear gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

ASX:COH Recettes, dépenses et bénéfices (AUD Millions )
Date	Recettes	Les revenus	Dépenses G+A	Dépenses de R&D
30 Jun 24	2,236	357	898	277
31 Mar 24	2,193	354	886	273
31 Dec 23	2,149	350	874	270
30 Sep 23	2,043	326	842	257
30 Jun 23	1,936	301	810	245
31 Mar 23	1,824	281	768	230
31 Dec 22	1,713	261	725	215
30 Sep 22	1,681	275	691	213
30 Jun 22	1,648	289	658	211
31 Mar 22	1,612	273	628	208
31 Dec 21	1,575	257	597	205
30 Sep 21	1,536	291	579	200
30 Jun 21	1,498	324	560	195
31 Mar 21	1,403	82	549	187
31 Dec 20	1,308	-160	537	180
30 Sep 20	1,314	-199	550	182
30 Jun 20	1,321	-238	564	185
31 Mar 20	1,400	34	569	188
31 Dec 19	1,479	306	574	190
30 Sep 19	1,453	291	560	187
30 Jun 19	1,427	277	546	184
31 Mar 19	1,422	270	535	180
31 Dec 18	1,418	264	525	175
30 Sep 18	1,391	255	510	172
30 Jun 18	1,364	246	494	168
31 Mar 18	1,329	234	475	164
31 Dec 17	1,294	223	456	160
30 Sep 17	1,274	223	444	156
30 Jun 17	1,254	224	432	152
31 Mar 17	1,218	215	426	149
31 Dec 16	1,182	206	420	146
30 Sep 16	1,156	198	412	146
30 Jun 16	1,131	189	403	145
31 Mar 16	1,088	179	383	142
31 Dec 15	1,045	168	362	138
30 Sep 15	986	157	341	133
30 Jun 15	926	146	320	128
31 Mar 15	899	145	308	126
31 Dec 14	872	144	296	124
30 Sep 14	839	119	288	126
30 Jun 14	805	94	279	128
31 Mar 14	769	85	267	129
31 Dec 13	732	76	256	130
30 Sep 13	742	104	248	127

Des revenus de qualité: COH a des bénéfices de haute qualité.

Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de COH (16%) sont supérieures à celles de l'année dernière (15.5%).

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: Les bénéfices de COH ont augmenté de manière significative de 22.8% par an au cours des 5 dernières années.

Accélération de la croissance: La croissance des bénéfices de COH au cours de l'année écoulée ( 18.7% ) est inférieure à sa moyenne sur 5 ans ( 22.8% par an).

Bénéfices par rapport au secteur d'activité: La croissance des bénéfices COH au cours de l'année écoulée ( 18.7% ) a dépassé celle du secteur Medical Equipment 10.1%.

Rendement des fonds propres

ROE élevé: Le retour sur capitaux propres de COH ( 19.4% ) est considéré comme faible.

Cochlear Résultats passés

Passé contrôle des critères 4/6

Informations clés

Mises à jour récentes des performances passées

Full year 2024 earnings: EPS misses analyst expectations

First half 2024 earnings: EPS in line with expectations, revenues disappoint

Cochlear Limited to Report Fiscal Year 2024 Results on Aug 15, 2024

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2022 earnings: EPS misses analyst expectations

Cochlear Limited to Report First Half, 2023 Results on Feb 15, 2023

Recent updates

Final dividend of AU$2.10 announced

Cochlear Limited Announces Ordinary Dividend for the Period of Six Months Ended June 30, 2024, Payable on October 10, 2024

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Full year 2024 earnings: EPS misses analyst expectations

Cochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.

Investors Could Be Concerned With Cochlear's (ASX:COH) Returns On Capital

Cochlear Limited Appoints Caroline Clarke as Non-Executive Director, Effective from 2 September 2024

Cochlear Limited Announces Executive Changes

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Cochlear Limited Announces Company Secretary Changes

Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Upcoming dividend of AU$2.00 per share

First half dividend increased to AU$2.00

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

First half 2024 earnings: EPS in line with expectations, revenues disappoint

Price target increased by 7.0% to AU$272

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

Cochlear (ASX:COH) Could Be Struggling To Allocate Capital

Upcoming dividend of AU$1.75 per share at 1.2% yield

Cochlear Limited Introduces Next Generation Cochlear Osia System with Ability to Have MRI at 3.0 T

Cochlear Limited to Report Fiscal Year 2024 Results on Aug 15, 2024

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Cochlear Limited Announces Andrew Denver, Non-Executive Director Intention to Retire At AGM to Be Held on 17 October 2023

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

Upcoming dividend of AU$1.55 per share at 1.3% yield

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Cochlear Limited Provides Earnings Outlook for the Year 2023

Cochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.

Is Cochlear (ASX:COH) A Risky Investment?

Cochlear Limited, Annual General Meeting, Oct 17, 2023

Is Cochlear Limited (ASX:COH) Worth AU$205 Based On Its Intrinsic Value?

FDA Approves Cochlear Limited's Nucleus 8 Sound Processor, Smaller, Smarter, Better Connected Cochlear Implant Technology

Key Executive recently bought AU$97k worth of stock

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Should Shareholders Reconsider Cochlear Limited's (ASX:COH) CEO Compensation Package?

Upcoming dividend of AU$1.45 per share

Cochlear's (ASX:COH) Upcoming Dividend Will Be Larger Than Last Year's

Here's Why Cochlear (ASX:COH) Can Manage Its Debt Responsibly

Full year 2022 earnings: EPS misses analyst expectations

Cochlear Announces Final Dividend Payable on 17 October 2022

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Cochlear Limited Appoints Karen Penrose to Board, Effective on 1 July 2022

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

Cochlear Limited, Annual General Meeting, Oct 18, 2022

Cochlear Limited to Report First Half, 2023 Results on Feb 15, 2023

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Upcoming dividend of AU$1.55 per share

Investor sentiment improved over the past week

First half 2022 earnings: EPS and revenues exceed analyst expectations

Cochlear Limited Announces Interim Dividend Expected to Be Payable on 21 April 2022

Estimating The Intrinsic Value Of Cochlear Limited (ASX:COH)

FDA Approves Cochlear Nucleus Implants for Unilateral Hearing Loss/Single-Sided Deafness

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Independent Non-Executive Director recently bought AU$56k worth of stock

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

This Is Why We Think Cochlear Limited's (ASX:COH) CEO Might Get A Pay Rise Approved By Shareholders

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

Cochlear Limited Advises of US Patent Infringement Complaint

Upcoming dividend of AU$1.40 per share

CEO, MD exercised options and sold AU$295k worth of stock

Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear Implantation

Independent Non-Executive Director recently bought AU$94k worth of stock

Independent Chairman Roderic Holliday-Smith has left the company

Independent Chairman Roderic Holliday-Smith has left the company

Full year 2021 earnings released: EPS AU$4.97 (vs AU$4.00 loss in FY 2020)